A Phase 1/2 interventional study of Avelumab and PF-06463922 in Non-Small Cell Lung Cancer, sponsored by Pfizer. Terminated at 20 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-07-07.
Sponsored by Pfizer · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 27 studies testing lorlatinib in Carcinoma, Non-Small-Cell Lung — 8 open to participants now, 16 under way, 1 of them phase 3. lorlatinib · Carcinoma, Non-Small-Cell Lung.
Among the 27 studies testing lorlatinib in Carcinoma, Non-Small-Cell Lung, this one is the 15th largest by enrollment, is the only one that started in 2015, is one of 3 in phase 1/2, and was the 2nd registered.
7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.
Browse Carcinoma, Non-Small-Cell Lung studies →8 of the 27 studies testing lorlatinib in Carcinoma, Non-Small-Cell Lung are open now, in 5 countries. Recruiting first, the newest first:
Chugai Pharmaceutical · Sites in United States, Japan
Ages 18+
M.D. Anderson Cancer Center · Sites in United States
Ages 18+
Pfizer · Sites in France
Ages 18+
Centro di Riferimento Oncologico - Aviano · Sites in Italy
Ages 18+
Guangdong Association of Clinical Trials · Sites in China
Ages 18+
By country, each count listing its studies:
lorlatinib: first FDA approval 2018 (LORBRENA), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →
Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
27 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 19 · Phase 3 1 · Phase 4 3
First in 2014; this study’s year is marked. 1 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 43 is below the median of 62 across 6,024 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.
Median enrollment 45 across the 27 interventional studies. Of the 7 that completed or were terminated, 4 (57%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 27 have an industry lead sponsor. The 10 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
158 studies in Carcinoma, Non-Small-Cell Lung by Pfizer: 15 open now, 26 under way, 5 of them phase 3. Of 123 finished, 70 (57%) have results posted.
Among the 158 studies in Carcinoma, Non-Small-Cell Lung by Pfizer, this one is the 88th largest by enrollment of the 136 interventional ones that give a count, is one of 11 that started in 2015, is one of 13 in phase 1/2, and was the 71st registered.
Pfizer’s Carcinoma, Non-Small-Cell Lung studies by the year they started, since 1999.
1 of the studies testing lorlatinib in Carcinoma, Non-Small-Cell Lung that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07083687Hunan Cancer HospitalLorlatinib in ROS1+ NSCLC With Brain Metastasis | 2027-01-01 |
Add it to your calendar (.ics) → With an account.
Among the 27 studies testing lorlatinib in Carcinoma, Non-Small-Cell Lung, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Pfizer’s 158 in Carcinoma, Non-Small-Cell Lung:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the safety and efficacy of avelumab when combined with either crizotinib or PF-06463922.
This is a Phase 1b/2, open label, multi center, multiple dose, safety, pharmacokinetic and pharmacodynamic study of Group A and Group B in cohorts of adult patients with locally advanced or metastatic NSCLC.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALK negative Non-Small Cell Lung Cancer
Drug: Avelumab · Drug: Crizotinib
ALK positive Non-Small Cell Lung Cancer
Drug: Avelumab · Drug: PF-06463922
Administered by IV once every two weeks in doses of either 5 mg/kg or 10 mg/kg
Also known as: MSB0010718C
Tablets taken orally once every day in doses of either 100mg, 75mg, or 50mg.
Capsules. Taken orally once or twice every day in doses of either 200mg or 250mg.
Also known as: PF-02341066
Number of Participants With Dose-limiting Toxicities (DLTs): Phase 1b
Any of the following adverse events (AEs) occurring during the primary DLT observation period that are attributable to one, the other, or both study drugs were classified as DLTs: Grade 4 (life-threatening) neutropenia if \>7 days in duration; febrile neutropenia; Grade \>=3 (severe or life threatening) neutropenic infection; Grade \>=3 thrombocytopenia with bleeding; Grade 4 thrombocytopenia \>7 days; Grade 4 anemia; any Grade \>=3 toxicity, except for any of the following: transient (\<=6 hours) Grade 3 (severe) flu like symptoms or fever; transient (\<=24 hours) Grade 3 fatigue, local reactions, or headache that resolved to Grade \<=1 (no AE or mild AE); Grade 3 nausea and/or vomiting, diarrhea or skin toxicity that resolved to Grade \<=1 within 7 days; any Grade \>=3 amylase or lipase abnormality; tumor flare phenomenon; single laboratory values out of normal range that were not related to treatment, did not have any clinical correlate, and resolve to Grade \<=1 within 7 days.
Time frame: First 2 cycles (1 cycle = 14 days)
Percentage of Participants With Objective Response (OR): Phase 2
OR is defined as complete response (CR) or partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 from start date (the date of first dose of study treatment) until disease progression or death due to any cause. Both CR and PR must be confirmed by repeat assessments performed no less than 4 weeks after the criteria for response are first met. Per RECIST v1.1: CR is defined as the disappearance of all target or non-target lesions; any pathological lymph nodes (whether target or non target) must have reduction in short axis to \<10 mm and all lymph nodes must be non-pathological in size (\<10 mm short axis). PR is defined as a \>=30% decrease in the sum of the longest dimensions of the target lesions taking as a reference the baseline sum longest dimensions.
Time frame: Screening, Day 1 of each cycle starting Cycle 3, up to end of treatment/withdrawal (maximum of 5 years)
Percentage of Participants With CR for Group B: Phase 2
Per RECIST v1.1: CR is defined as the disappearance of all target or non-target lesions; any pathological lymph nodes (whether target or non target) must have reduction in short axis to \<10 mm and all lymph nodes must be non-pathological in size (\<10 mm short axis).
Time frame: Baseline up to 60 months
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
TEAEs are those events with onset dates occurring during the on-treatment period for the first time, or if the worsening of an event is during the on-treatment period. Treatment-related AEs was any untoward medical occurrence attributed to study drug in a participant who received study drug. Per National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v4.03: Grade 3 (Severe) events=unacceptable or intolerable events, significantly interrupting usual daily activity, require systemic drug therapy/other treatment; Grade 4 (Life-threatening) events caused participant to be in imminent danger of death; Grade 5 (Death) events=death related to an AE. A serious AE (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged in participant hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.
Time frame: Baseline up to 30 days after last dose of study treatment or the day before start day of new anti-cancer therapy (maximum of 5 years)
Number of Participants With Baseline Laboratory Abnormalities Grade <=2 and Post-Baseline Laboratory Abnormalities of Grades 3 or 4 Per NCI CTCAE v4.03
The laboratory results were graded according to the NCI CTCAE v4.03 severity grade. Grade 1=mild AE. Grade 2=moderate AE. Grade 3=severe AE. Grade 4=life-threatening consequences; urgent intervention indicated. Shift tables were provided to examine the distribution of laboratory toxicities. The following parameters had met the criteria of CTCAE grade shift change from Grade \<=2 at baseline to Grade 3 or 4 post baseline: anemia, lymphocyte count decreased, lymphocyte count decreased, neutrophil count decreased, white blood cell decreased, alanine aminotransferase increased, aspartate aminotransferase increased, blood bilirubin increased, cholesterol high, Creatine phosphokinase (CPK) increased, Gamma glutamyl transferase (GGT) increased, hypercalcemia, hyperglycemia, hypermagnesemia, hypertriglyceridemia, hypoalbuminemia, hyponatremia, lipase increased, serum amylase increased. Baseline is defined as the last assessment prior to the date/time of the first dose of study treatment.
Time frame: Screening up to end of treatment/withdrawal (maximum of 5 years)
Number of Participants With Vital Signs Meeting Pre-defined Criteria
Pre-defined criteria in vital signs: pulse rate \<50 beats per minute, pulse rate \>120 bpm, sitting diastolic blood pressure (DBP) increase and decrease in change from baseline of \>= 20 millimeter of mercury (mmHg), sitting systolic blood pressure(SBP) \< 90 mmHg, increase and decrease in change from baseline of \>= 30mmHg. Baseline is defined as the last assessment prior to the date/time of the first dose of study treatment.
Time frame: Screening up to end of treatment/withdrawal (maximum of 5 years)
Disease Control Rate (DCR)
DC is defined as objective response (CR or PR) or stable disease (SD) per RECIST v.1.1 from the date of first dose of study treatment until disease progression or death due to any cause. The DCR is the proportion of patients with DC. Per RECIST v1.1: CR is defined as the disappearance of all target or non-target lesions; any pathological lymph nodes (whether target or non target) must have reduction in short axis to \<10 mm. PR is defined as a \>=30% decrease in the sum of the longest dimensions of the target lesions taking as a reference the baseline sum longest dimensions. SD is defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD). PD is defined as a \>=20% increase in the sum of the longest dimensions of the target lesions taking as a reference the smallest sum of the longest dimensions recorded since the treatment started, or the appearance of one or more new lesions.
Time frame: Screening, Day 1 of each cycle starting Cycle 3, up to end of treatment/withdrawal (maximum of 5 years)
Duration of Response (DR)
DR: time from first documented occurrence of response (PR or CR) until date of first documented PD or death due to underlying cancer. Per RECIST 1.1: CR: disappearance of all non-nodal target lesions and of all non-target lesions; any pathological lymph nodes assigned as target lesions/non-target lesions have a reduction in short axis to \<10 mm. PR: at least a \>=30% decrease in sum of diameter of all target lesions, taking as reference baseline sum of diameters. PD: at least a \>=20% increase in sum of diameter of all measured target lesions, taking as reference the smallest sum of diameter of all target lesions recorded at or after baseline. In addition to the relative increase of 20%, sum must also demonstrate an absolute increase of at least 5 mm. Unequivocal progression of existing non-target lesions. Appearance of new lesions. Participants with no PD and were still alive by 02 Feb 2020, were censored at last adequate tumor assessment. Kaplan-Meier method was used for DR analysis.
Time frame: Screening, Day 1 of each cycle starting Cycle 3, up to end of treatment/withdrawal (maximum of 5 years)
Time to Tumor Response (TTR)
TTR is defined, for participants with an objective response (CR or PR), as the time from the start date (the date of first dose of treatment) to the first documentation of objective response (CR or PR) which is subsequently confirmed. Per RECIST v1.1: CR: disappearance of all non-nodal target lesions and of all non-target lesions. In addition, any pathological lymph nodes assigned as target lesions/ non-target lesions must have a reduction in short axis to \<10 mm. PR: at least a 30% decrease in sum of diameter of all target lesions, taking as reference baseline sum of diameters.
Time frame: Screening, Day 1 of each cycle starting Cycle 3, up to end of treatment/withdrawal (maximum of 5 years)
Progression-free Survival (PFS)
PFS is defined as the time from start date (the date of first dose of treatment) to the date of the first documentation of PD per RECIST v1.1 or death due to any cause, whichever occurs first. Per RECIST v1.1: PD: a \>=20% increase in the sum of the longest dimensions of the target lesions taking as a reference the smallest sum of the longest dimensions recorded since the treatment started, or the appearance of one or more new lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.
Time frame: Screening, Day 1 of each cycle starting Cycle 3, up to end of treatment/withdrawal (maximum of 5 years)
Kaplan-Meier Estimates of Overall Survival (OS)
OS is defined as the time from start date (the date of first dose of treatment) to the date of death due to any cause.
Time frame: Screening, Day 1 of each cycle starting Cycle 3, up to end of treatment/withdrawal (maximum of 5 years)
Maximum Plasma Concentration (Cmax) of Crizotinib in The Presence of Avelumab
Cmax of crizotinib in the presence of avelumab was observed directly from data.
Time frame: Pre-dose, 1, 2, 4, 6 and 8 hours post dose on Day 1 of Cycle 2
Time to Cmax (Tmax) of Crizotinib in The Presence of Avelumab
Tmax of crizotinib in the presence of avelumab was observed directly from data as time of first occurrence.
Time frame: Pre-dose, 1, 2, 4, 6 and 8 hours post dose on Day 1 of Cycle 2
Area Under The Plasma Concentration-Time Curve During The Dosing Interval Time Course (AUCtau) of Crizotinib in The Presence of Avelumab
AUCtau of crizotinib in the presence of avelumab was calculated by Linear/Log trapezoidal method. Dose interval is defined as after single dose from time zero to the next dose (after single dose and at steady state).
Time frame: Pre-dose, 1, 2, 4, 6 and 8 hours post dose on Day 1 of Cycle 2
Apparent Plasma Clearance (CL/F) of Crizotinib in The Presence of Avelumab
Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Clearance was estimated from population pharmacokinetic (PK) modeling. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.
Time frame: Pre-dose, 1, 2, 4, 6 and 8 hours post dose on Day 1 of Cycle 2
Cmax of Crizotinib Metabolite PF-06260182 in The Presence of Avelumab
Cmax of crizotinib metabolite PF-06260182 in the presence of avelumab was observed directly from data.
Time frame: Pre-dose, 1, 2, 4, 6 and 8 hours post dose on Day 1 of Cycle 2
Tmax of Crizotinib Metabolite PF-06260182 in The Presence of Avelumab
Tmax of crizotinib metabolite PF-06260182 in the presence of avelumab was observed directly from data as time of first occurrence.
Time frame: Pre-dose, 1, 2, 4, 6 and 8 hours post dose on Day 1 of Cycle 2
AUCtau of Crizotinib Metabolite PF-06260182 in The Presence of Avelumab
AUCtau of crizotinib metabolite PF-06260182 in the presence of avelumab was calculated by Linear/Log trapezoidal method. Dose interval: single dose from time zero to the next dose (after single dose and at steady state).
Time frame: Pre-dose, 1, 2, 4, 6 and 8 hours post dose on Day 1 of Cycle 2
Metabolite to Parent Ratio for AUCtau (MRAUCtau) of PF-06260182 in The Presence of Avelumab
MRAUCtau of metabolite PF-06260182 in the presence of avelumab was calculated (MRAUCtau=Metabolite AUCtau/parent AUCtau). Parent=crizotinib, metabolite=PF-06260182
Time frame: Pre-dose, 1, 2, 4, 6 and 8 hours post dose on Day 1 of Cycle 2
Metabolite to Parent Ratio for Cmax (MRCmax) of PF-06260182 in The Presence of Avelumab
MRCmax of metabolite PF-06260182 in the presence of avelumab was calculated (MRCmax=Metabolite Cmax/parent Cmax). Parent=crizotinib, metabolite=PF-06260182
Time frame: Pre-dose, 1, 2, 4, 6 and 8 hours post dose on Day 1 of Cycle 2
Cmax of Lorlatinib in The Presence of Avelumab
Cmax of lorlatinib in the presence of avelumab was observed directly from data.
Time frame: Pre-dose, 1, 2, 4, 6, 8, and 24 hours (prior to Day 2 lorlatinib dose) post dose on Day 1 of Cycle 2
Tmax of Lorlatinib in The Presence of Avelumab
Tmax of lorlatinib in the presence of avelumab was observed directly from data.
Time frame: Pre-dose, 1, 2, 4, 6, 8, and 24 hours (prior to Day 2 lorlatinib dose) post dose on Day 1 of Cycle 2
AUCtau of Lorlatinib in The Presence of Avelumab
AUCtau of lorlatinib in the presence of avelumab was calculated by Linear/Log trapezoidal method. Dose interval: single dose from time zero to the next dose (after single dose and at steady state).
Time frame: Pre-dose, 1, 2, 4, 6, 8, and 24 hours (prior to Day 2 lorlatinib dose) post dose on Day 1 of Cycle 2
Area Under The Plasma Concentration Time Curve From Time of Dosing to The Last Collection Time Point (AUClast) of Lorlatinib in The Presence of Avelumab
AUClast of lorlatinib in the presence of avelumab.
Time frame: Pre-dose, 1, 2, 4, 6, 8, and 24 hours (prior to Day 2 lorlatinib dose) post dose on Day 1 of Cycle 2
CL/F of Lorlatinib in The Presence of Avelumab
Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Clearance was estimated from population PK modeling. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.
Time frame: Pre-dose, 1, 2, 4, 6, 8, and 24 hours (prior to Day 2 lorlatinib dose) post dose on Day 1 of Cycle 2
Cmax of Avelumab in The Presence of Crizotinib (Group A) or Lorlatinib (Group B) After Single Dose of Avelumab
Cmax of avelumab in the presence of crizotinib was observed directly from the data in Group A. Cmax of avelumab in the presence of lorlatinib was observed directly from the data in Group B.
Time frame: Pre-dose, 1, and 168 hours post dose of avelumab on Cycle 1 Day 1.
Cmax of Avelumab in The Presence of Crizotinib (Group A) or Lorlatinib (Group B) After Multiple Doses of Avelumab
Cmax of avelumab in the presence of crizotinib was observed directly from the data in Group A. Cmax of avelumab in the presence of lorlatinib was observed directly from the data in Group B.
Time frame: Pre-dose, 1, and 168 hours post dose of avelumab on Cycle 2 Day 1
Trough Serum Concentration (Ctrough) of Avelumab in The Presence of Crizotinib (Group A) Following Multiple Doses of Avelumab
Ctrough is defined as predose concentration following multiple doses. Ctrough of avelumab in the presence of crizotinib was observed directly from the data in Group A.
Time frame: Pre-dose on Day 1 of Cycles 2-5, 11, 17, 23, 29, 35, and 47.
Trough Serum Concentration (Ctrough) of Avelumab in The Presence of Lorlatinib (Group B) Following Multiple Doses of Avelumab
Ctrough is defined as predose concentration following multiple doses. Ctrough of avelumab in the presence of lorlatinib was observed directly from the data in Group B.
Time frame: Pre-dose on Day 1 of Cycles 2-5, 11, 17, 23, 29, 35, 41, and 47.
Number of Participants With Anti-Drug Antibodies (ADA) Against Avelumab by Never and Ever Positive Status
ADA never-positive was defined as no positive ADA results at any time point. ADA ever-positive was defined as at least one positive ADA result at any time point. Baseline is defined as the last assessment on or prior to the date/time of the first dose of avelumab.
Time frame: Day 1 of Cycles 1-5, then every 12 weeks thereafter, end of treatment/withdrawal, and 30 days after last avelumab dose (up to a maximum of 5 years)
Number of Participants With Positive Programmed Death Ligand-1 (PD-L1) Biomarker Expression
PD-L1 protein expression is determined by using Combined Positive Score (CPS), which is the percentage of viable tumor and tumor-infiltrated immune cells (restricted to lymphocytes and macrophages) within or directly associated with tumor cell strands showing partial or complete membrane staining using the SP263 antibody. Positive is defined as CPS\>=1% and negative is defined as CPS \<1%.
Time frame: Baseline
Number of Participants With Positive Tumor Infiltrating CD8+ Lymphocytes
Tumor infiltrating CD8+ lymphocytes is defined as the number of CD8+ cells per unit area and the percent of counted cells. Positive is defined as \>=1% and negative is defined as \<1%.
Time frame: Baseline
| Milestone | Group A: Avelumab + Crizotinib | Group B: Avelumab + Lorlatinib |
|---|---|---|
| Started | 12 | 31 |
| Completed | 0 | 0 |
| Not completed | 12 | 31 |
| Withdrew: Adverse event | 3 | 5 |
| Withdrew: Death | 0 | 1 |
| Withdrew: Lost to follow-up | 0 | 1 |
| Withdrew: Physician decision | 1 | 2 |
| Withdrew: Progressive disease | 7 | 15 |
| Withdrew: Withdrawal by subject | 1 | 1 |
| Withdrew: Other | 0 | 6 |
Any of the following adverse events (AEs) occurring during the primary DLT observation period that are attributable to one, the other, or both study drugs were classified as DLTs: Grade 4 (life-threatening) neutropenia if \>7 days in duration; febrile neutropenia; Grade \>=3 (severe or life threatening) neutropenic infection; Grade \>=3 thrombocytopenia with bleeding; Grade 4 thrombocytopenia \>7 days; Grade 4 anemia; any Grade \>=3 toxicity, except for any of the following: transient (\<=6 hours) Grade 3 (severe) flu like symptoms or fever; transient (\<=24 hours) Grade 3 fatigue, local reactions, or headache that resolved to Grade \<=1 (no AE or mild AE); Grade 3 nausea and/or vomiting, diarrhea or skin toxicity that resolved to Grade \<=1 within 7 days; any Grade \>=3 amylase or lipase abnormality; tumor flare phenomenon; single laboratory values out of normal range that were not related to treatment, did not have any clinical correlate, and resolve to Grade \<=1 within 7 days.
| Participants | Group A: Avelumab + Crizotinib | Group B: Avelumab + Lorlatinib |
|---|---|---|
| Number of Participants With Dose-limiting Toxicities (DLTs): Phase 1b | 5 | 2 |
OR is defined as complete response (CR) or partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 from start date (the date of first dose of study treatment) until disease progression or death due to any cause. Both CR and PR must be confirmed by repeat assessments performed no less than 4 weeks after the criteria for response are first met. Per RECIST v1.1: CR is defined as the disappearance of all target or non-target lesions; any pathological lymph nodes (whether target or non target) must have reduction in short axis to \<10 mm and all lymph nodes must be non-pathological in size (\<10 mm short axis). PR is defined as a \>=30% decrease in the sum of the longest dimensions of the target lesions taking as a reference the baseline sum longest dimensions.
| Percentage of participants | Group A: Avelumab + Crizotinib | Group B: Avelumab + Lorlatinib |
|---|---|---|
| Percentage of Participants With Objective Response (OR): Phase 2 | 25.0 (5.5 to 57.2) | 51.6 (33.1 to 69.8) |
Per RECIST v1.1: CR is defined as the disappearance of all target or non-target lesions; any pathological lymph nodes (whether target or non target) must have reduction in short axis to \<10 mm and all lymph nodes must be non-pathological in size (\<10 mm short axis).
| Percentage of participants | Group B: Avelumab + Lorlatinib |
|---|---|
| Percentage of Participants With CR for Group B: Phase 2 | 3.2 |
TEAEs are those events with onset dates occurring during the on-treatment period for the first time, or if the worsening of an event is during the on-treatment period. Treatment-related AEs was any untoward medical occurrence attributed to study drug in a participant who received study drug. Per National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v4.03: Grade 3 (Severe) events=unacceptable or intolerable events, significantly interrupting usual daily activity, require systemic drug therapy/other treatment; Grade 4 (Life-threatening) events caused participant to be in imminent danger of death; Grade 5 (Death) events=death related to an AE. A serious AE (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged in participant hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.
| Participants | Group A: Avelumab + Crizotinib | Group B: Avelumab + Lorlatinib |
|---|---|---|
| Participants with TEAEs | 12 | 30 |
| Participants with Grade >= 3 TEAEs | 7 | 23 |
| Participants with treatment-related TEAEs | 12 | 28 |
| Participants with Grade >= 3 treatment-related TEAEs | 6 | 16 |
| Participants with SAEs | 5 | 21 |
| Participants with treatment-related SAEs | 2 | 6 |
| Participants with TEAEs leading to discontinuation of avelumab | 3 | 10 |
| Participants with TEAEs leading to discontinuation of crizotinib | 6 | — |
| Participants with TEAEs leading to discontinuation of lorlatinib | — | 2 |
| Participants with TEAEs leading to discontinuation of any study drug | 6 | 10 |
| Participants with TEAEs leading to discontinuation of all study drugs | 3 | 1 |
| Participants with treatment-related TEAEs leading to discontinuation of avelumab | 2 | 9 |
| Participants with treatment-related TEAEs leading to discontinuation of crizotinib | 5 | — |
| Participants with treatment-related TEAEs leading to discontinuation of lorlatinib | — | 2 |
| Participants with TEAEs leading to death | 1 | 4 |
| Participants with treatment-related TEAEs leading to death | 0 | 1 |
| Participants with infusion-related reactions | 5 | 9 |
The laboratory results were graded according to the NCI CTCAE v4.03 severity grade. Grade 1=mild AE. Grade 2=moderate AE. Grade 3=severe AE. Grade 4=life-threatening consequences; urgent intervention indicated. Shift tables were provided to examine the distribution of laboratory toxicities. The following parameters had met the criteria of CTCAE grade shift change from Grade \<=2 at baseline to Grade 3 or 4 post baseline: anemia, lymphocyte count decreased, lymphocyte count decreased, neutrophil count decreased, white blood cell decreased, alanine aminotransferase increased, aspartate aminotransferase increased, blood bilirubin increased, cholesterol high, Creatine phosphokinase (CPK) increased, Gamma glutamyl transferase (GGT) increased, hypercalcemia, hyperglycemia, hypermagnesemia, hypertriglyceridemia, hypoalbuminemia, hyponatremia, lipase increased, serum amylase increased. Baseline is defined as the last assessment prior to the date/time of the first dose of study treatment.
| Participants | Group A: Avelumab + Crizotinib | Group B: Avelumab + Lorlatinib |
|---|---|---|
| Anemia | 0 | 3 |
| Lymphocyte count decreased | 1 | 2 |
| Lymphocyte count increased | 0 | 2 |
| Neutrophil count decreased | 1 | 0 |
| White blood cell decreased | 1 | 0 |
| Alanine aminotransferase increased | 3 | 0 |
| Aspartate aminotransferase increased | 2 | 1 |
| Blood bilirubin increased | 0 | 1 |
| Cholesterol high | 0 | 5 |
| CPK increased | 0 | 2 |
| GGT increased | 1 | 5 |
| Hypercalcemia | 0 | 2 |
| Hyperglycemia | 1 | 1 |
| Hypermagnesemia | 0 | 1 |
| Hypertriglyceridemia | 0 | 7 |
| Hypoalbuminemia | 0 | 1 |
| Hyponatremia | 1 | 3 |
| Lipase increased | 1 | 5 |
| Serum amylase increased | 0 | 1 |
| Hemoglobin increased | 0 | 0 |
| Platelet count decreased | 0 | 0 |
| Alkaline phosphatase increased | 0 | 0 |
| Creatinine increased | 0 | 0 |
| Hyperkalemia | 0 | 0 |
| Hypernatremia | 0 | 0 |
| Hypocalcemia | 0 | 0 |
| Hypoglycemia | 0 | 0 |
| Hypokalemia | 0 | 0 |
| Hypomagnesemia | 0 | 0 |
| Hypophosphatemia | 0 | 0 |
Pre-defined criteria in vital signs: pulse rate \<50 beats per minute, pulse rate \>120 bpm, sitting diastolic blood pressure (DBP) increase and decrease in change from baseline of \>= 20 millimeter of mercury (mmHg), sitting systolic blood pressure(SBP) \< 90 mmHg, increase and decrease in change from baseline of \>= 30mmHg. Baseline is defined as the last assessment prior to the date/time of the first dose of study treatment.
| Participants | Group A: Avelumab + Crizotinib | Group B: Avelumab + Lorlatinib |
|---|---|---|
| Pulse rate <50 bpm | 2 | 0 |
| Pulse rate >120 bpm | 0 | 4 |
| Sitting DBP change >= 20 mmHg increase | 2 | 13 |
| Sitting DBP change >= 20 mmHg decrease | 5 | 8 |
| Sitting SBP <90 mmHg | 1 | 4 |
| Sitting SBP change >= 30 mmHg increase | 1 | 11 |
| Sitting SBP change >= 30 mmHg decrease | 3 | 2 |
DC is defined as objective response (CR or PR) or stable disease (SD) per RECIST v.1.1 from the date of first dose of study treatment until disease progression or death due to any cause. The DCR is the proportion of patients with DC. Per RECIST v1.1: CR is defined as the disappearance of all target or non-target lesions; any pathological lymph nodes (whether target or non target) must have reduction in short axis to \<10 mm. PR is defined as a \>=30% decrease in the sum of the longest dimensions of the target lesions taking as a reference the baseline sum longest dimensions. SD is defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD). PD is defined as a \>=20% increase in the sum of the longest dimensions of the target lesions taking as a reference the smallest sum of the longest dimensions recorded since the treatment started, or the appearance of one or more new lesions.
| Percentage of participants | Group A: Avelumab + Crizotinib | Group B: Avelumab + Lorlatinib |
|---|---|---|
| Disease Control Rate (DCR) | 58.3 (27.7 to 84.8) | 71.0 (52.0 to 85.8) |
DR: time from first documented occurrence of response (PR or CR) until date of first documented PD or death due to underlying cancer. Per RECIST 1.1: CR: disappearance of all non-nodal target lesions and of all non-target lesions; any pathological lymph nodes assigned as target lesions/non-target lesions have a reduction in short axis to \<10 mm. PR: at least a \>=30% decrease in sum of diameter of all target lesions, taking as reference baseline sum of diameters. PD: at least a \>=20% increase in sum of diameter of all measured target lesions, taking as reference the smallest sum of diameter of all target lesions recorded at or after baseline. In addition to the relative increase of 20%, sum must also demonstrate an absolute increase of at least 5 mm. Unequivocal progression of existing non-target lesions. Appearance of new lesions. Participants with no PD and were still alive by 02 Feb 2020, were censored at last adequate tumor assessment. Kaplan-Meier method was used for DR analysis.
| Month | Group A: Avelumab + Crizotinib | Group B: Avelumab + Lorlatinib |
|---|---|---|
| Duration of Response (DR) | 3.7 (3.7 to 4.6) | 14.7 (3.7 to NA) |
TTR is defined, for participants with an objective response (CR or PR), as the time from the start date (the date of first dose of treatment) to the first documentation of objective response (CR or PR) which is subsequently confirmed. Per RECIST v1.1: CR: disappearance of all non-nodal target lesions and of all non-target lesions. In addition, any pathological lymph nodes assigned as target lesions/ non-target lesions must have a reduction in short axis to \<10 mm. PR: at least a 30% decrease in sum of diameter of all target lesions, taking as reference baseline sum of diameters.
| Months | Group A: Avelumab + Crizotinib | Group B: Avelumab + Lorlatinib |
|---|---|---|
| Time to Tumor Response (TTR) | 1.4 (1.4 to 6.9) | 1.8 (1.3 to 3.7) |
PFS is defined as the time from start date (the date of first dose of treatment) to the date of the first documentation of PD per RECIST v1.1 or death due to any cause, whichever occurs first. Per RECIST v1.1: PD: a \>=20% increase in the sum of the longest dimensions of the target lesions taking as a reference the smallest sum of the longest dimensions recorded since the treatment started, or the appearance of one or more new lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.
| Months | Group A: Avelumab + Crizotinib | Group B: Avelumab + Lorlatinib |
|---|---|---|
| Progression-free Survival (PFS) | 3.7 (1.5 to 5.5) | 6.4 (3.7 to 9.2) |
OS is defined as the time from start date (the date of first dose of treatment) to the date of death due to any cause.
| Months | Group A: Avelumab + Crizotinib | Group B: Avelumab + Lorlatinib |
|---|---|---|
| Kaplan-Meier Estimates of Overall Survival (OS) | 16.4 (5.4 to 27.6) | 32.9 (10.7 to NA) |
Cmax of crizotinib in the presence of avelumab was observed directly from data.
| nanograms per millilitre (ng/mL) | Group A: Avelumab + Crizotinib |
|---|---|
| Maximum Plasma Concentration (Cmax) of Crizotinib in The Presence of Avelumab | 281 ± 74 |
Tmax of crizotinib in the presence of avelumab was observed directly from data as time of first occurrence.
| Hours | Group A: Avelumab + Crizotinib |
|---|---|
| Time to Cmax (Tmax) of Crizotinib in The Presence of Avelumab | 2.03 (0.00 to 8.08) |
AUCtau of crizotinib in the presence of avelumab was calculated by Linear/Log trapezoidal method. Dose interval is defined as after single dose from time zero to the next dose (after single dose and at steady state).
| nanograms*hours per millilitre (ng*h/mL) | Group A: Avelumab + Crizotinib |
|---|---|
| Area Under The Plasma Concentration-Time Curve During The Dosing Interval Time Course (AUCtau) of Crizotinib in The Presence of Avelumab | 2755 ± 82 |
Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Clearance was estimated from population pharmacokinetic (PK) modeling. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.
| Liter per hour (L/h) | Group A: Avelumab + Crizotinib |
|---|---|
| Apparent Plasma Clearance (CL/F) of Crizotinib in The Presence of Avelumab | 90.76 ± 82 |
Cmax of crizotinib metabolite PF-06260182 in the presence of avelumab was observed directly from data.
| ng/mL | Group A: Avelumab + Crizotinib |
|---|---|
| Cmax of Crizotinib Metabolite PF-06260182 in The Presence of Avelumab | 84.11 ± 91 |
Tmax of crizotinib metabolite PF-06260182 in the presence of avelumab was observed directly from data as time of first occurrence.
| Hours | Group A: Avelumab + Crizotinib |
|---|---|
| Tmax of Crizotinib Metabolite PF-06260182 in The Presence of Avelumab | 3.02 (0.00 to 8.08) |
AUCtau of crizotinib metabolite PF-06260182 in the presence of avelumab was calculated by Linear/Log trapezoidal method. Dose interval: single dose from time zero to the next dose (after single dose and at steady state).
| ng*h/mL | Group A: Avelumab + Crizotinib |
|---|---|
| AUCtau of Crizotinib Metabolite PF-06260182 in The Presence of Avelumab | 789.1 ± 116 |
MRAUCtau of metabolite PF-06260182 in the presence of avelumab was calculated (MRAUCtau=Metabolite AUCtau/parent AUCtau). Parent=crizotinib, metabolite=PF-06260182
| Ratio | Group A: Avelumab + Crizotinib |
|---|---|
| Metabolite to Parent Ratio for AUCtau (MRAUCtau) of PF-06260182 in The Presence of Avelumab | 0.2779 ± 33 |
MRCmax of metabolite PF-06260182 in the presence of avelumab was calculated (MRCmax=Metabolite Cmax/parent Cmax). Parent=crizotinib, metabolite=PF-06260182
| Ratio | Group A: Avelumab + Crizotinib |
|---|---|
| Metabolite to Parent Ratio for Cmax (MRCmax) of PF-06260182 in The Presence of Avelumab | 0.2902 ± 25 |
Cmax of lorlatinib in the presence of avelumab was observed directly from data.
| ng/mL | Group B: Avelumab + Lorlatinib |
|---|---|
| Cmax of Lorlatinib in The Presence of Avelumab | 596.9 ± 33 |
Tmax of lorlatinib in the presence of avelumab was observed directly from data.
| Hours | Group B: Avelumab + Lorlatinib |
|---|---|
| Tmax of Lorlatinib in The Presence of Avelumab | 1.23 (0.933 to 4.33) |
AUCtau of lorlatinib in the presence of avelumab was calculated by Linear/Log trapezoidal method. Dose interval: single dose from time zero to the next dose (after single dose and at steady state).
| ng*h/mL | Group B: Avelumab + Lorlatinib |
|---|---|
| AUCtau of Lorlatinib in The Presence of Avelumab | 5807 ± 42 |
AUClast of lorlatinib in the presence of avelumab.
| ng*h/mL | Group B: Avelumab + Lorlatinib |
|---|---|
| Area Under The Plasma Concentration Time Curve From Time of Dosing to The Last Collection Time Point (AUClast) of Lorlatinib in The Presence of Avelumab | 4872 ± 52 |
Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Clearance was estimated from population PK modeling. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.
| L/h | Group B: Avelumab + Lorlatinib |
|---|---|
| CL/F of Lorlatinib in The Presence of Avelumab | 16.97 ± 44 |
Cmax of avelumab in the presence of crizotinib was observed directly from the data in Group A. Cmax of avelumab in the presence of lorlatinib was observed directly from the data in Group B.
| micrograms/milliliter (ug/mL) | Group A: Avelumab + Crizotinib | Group B: Avelumab + Lorlatinib |
|---|---|---|
| Cmax of Avelumab in The Presence of Crizotinib (Group A) or Lorlatinib (Group B) After Single Dose of Avelumab | 193.2 ± 14 | 195.7 ± 28 |
Cmax of avelumab in the presence of crizotinib was observed directly from the data in Group A. Cmax of avelumab in the presence of lorlatinib was observed directly from the data in Group B.
| ug/mL | Group A: Avelumab + Crizotinib | Group B: Avelumab + Lorlatinib |
|---|---|---|
| Cmax of Avelumab in The Presence of Crizotinib (Group A) or Lorlatinib (Group B) After Multiple Doses of Avelumab | 174.5 ± 35 | 169.4 ± 68 |
Ctrough is defined as predose concentration following multiple doses. Ctrough of avelumab in the presence of crizotinib was observed directly from the data in Group A.
| ug/mL | Group A: Avelumab + Crizotinib |
|---|---|
| Cycle 2 Day 1 | 11.76 ± 68 |
| Cycle 3 Day 1 | 16.26 ± 53 |
| Cycle 4 Day 1 | 16.71 ± 34 |
| Cycle 5 Day 1 | 14.21 ± 46 |
| Cycle 11 Day 1 | 26.64 ± 4 |
| Cycle 17 Day 1 | 30.59 ± 9 |
| Cycle 23 Day 1 | 30.63 ± 15 |
| Cycle 29 Day 1 | 30.72 ± 55 |
| Cycle 35 Day 1 | 37.31 ± 27 |
| Cycle 47 Day 1 | 40.91 ± 15 |
Ctrough is defined as predose concentration following multiple doses. Ctrough of avelumab in the presence of lorlatinib was observed directly from the data in Group B.
| ug/mL | Group B: Avelumab + Lorlatinib |
|---|---|
| Cycle 2 Day 1 | 16.86 ± 88 |
| Cycle 3 Day 1 | 16.99 ± 116 |
| Cycle 4 Day 1 | 23.71 ± 80 |
| Cycle 5 Day 1 | 26.74 ± 68 |
| Cycle 11 Day 1 | 31.31 ± 71 |
| Cycle 17 Day 1 | 32.69 ± 60 |
| Cycle 23 Day 1 | 33.20 ± 56 |
| Cycle 29 Day 1 | 25.77 ± 66 |
| Cycle 35 Day 1 | 31.27 ± 47 |
| Cycle 41 Day 1 | 30.81 ± 59 |
| Cycle 47 Day 1 | 39.63 ± 64 |
ADA never-positive was defined as no positive ADA results at any time point. ADA ever-positive was defined as at least one positive ADA result at any time point. Baseline is defined as the last assessment on or prior to the date/time of the first dose of avelumab.
| Participants | Group A: Avelumab + Crizotinib | Group B: Avelumab + Lorlatinib | All Participants |
|---|---|---|---|
| ADA never-positive | 9 | 25 | 34 |
| ADA ever-positive | 3 | 6 | 9 |
PD-L1 protein expression is determined by using Combined Positive Score (CPS), which is the percentage of viable tumor and tumor-infiltrated immune cells (restricted to lymphocytes and macrophages) within or directly associated with tumor cell strands showing partial or complete membrane staining using the SP263 antibody. Positive is defined as CPS\>=1% and negative is defined as CPS \<1%.
| Participants | Group A: Avelumab + Crizotinib | Group B: Avelumab + Lorlatinib |
|---|---|---|
| Positive | 7 | 20 |
| Negative | 2 | 4 |
Tumor infiltrating CD8+ lymphocytes is defined as the number of CD8+ cells per unit area and the percent of counted cells. Positive is defined as \>=1% and negative is defined as \<1%.
| Participants | Group A: Avelumab + Crizotinib | Group B: Avelumab + Lorlatinib |
|---|---|---|
| Positive | 6 | 4 |
| Negative | 4 | 18 |
Collected over Baseline up to 30 days post lost dose of study treatment with a maximum of 5 years. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Group A: Avelumab + Crizotinib | 10/12 (83.3%) | 5/12 (41.7%) | 12/12 (100%) |
| Group B: Avelumab + Lorlatinib | 15/31 (48.4%) | 21/31 (67.7%) | 28/31 (90.3%) |
| Event | Group A: Avelumab + Crizotinib | Group B: Avelumab + Lorlatinib |
|---|---|---|
| PneumoniaInfections and infestations | 0/12 | 3/31 |
| Febrile neutropeniaBlood and lymphatic system disorders | 1/12 | 0/31 |
| Disease progressionGeneral disorders | 1/12 | 0/31 |
| Immune-mediated hepatitisHepatobiliary disorders | 1/12 | 0/31 |
| PneumonitisRespiratory, thoracic and mediastinal disorders | 1/12 | 2/31 |
| PneumothoraxRespiratory, thoracic and mediastinal disorders | 1/12 | 0/31 |
| RashSkin and subcutaneous tissue disorders | 1/12 | 0/31 |
| Confusional statePsychiatric disorders | 0/12 | 2/31 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 0/12 | 2/31 |
| Cardiac tamponadeCardiac disorders | 0/12 | 1/31 |
| Event | Group A: Avelumab + Crizotinib | Group B: Avelumab + Lorlatinib |
|---|---|---|
| Blood cholesterol increasedInvestigations | 0/12 | 19/31 |
| NauseaGastrointestinal disorders | 7/12 | 5/31 |
| HypertriglyceridaemiaMetabolism and nutrition disorders | 0/12 | 18/31 |
| VomitingGastrointestinal disorders | 6/12 | 6/31 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 0/12 | 13/31 |
| Decreased appetiteMetabolism and nutrition disorders | 5/12 | 2/31 |
| Oedema peripheralGeneral disorders | 1/12 | 12/31 |
| Alanine aminotransferase increasedInvestigations | 4/12 | 9/31 |
| RashSkin and subcutaneous tissue disorders | 4/12 | 5/31 |
| HypothyroidismEndocrine disorders | 0/12 | 8/31 |
The baseline analysis population included all participants who received at least one dose of study drug. Participants were classified according to the study treatment actually received. If a participant received more than one treatment the participant was classified according to the first treatment received.
| Age, Continuous(Years) | Group A: Avelumab + Crizotinib | Group B: Avelumab + Lorlatinib | Total |
|---|---|---|---|
| Mean | 58.67 ± 10.43 | 53.32 ± 11.59 | 54.81 ± 11.41 |
| Age, Customized(Participants) | Group A: Avelumab + Crizotinib | Group B: Avelumab + Lorlatinib | Total |
|---|---|---|---|
| <65 years | 9 | 25 | 7 |
| 65-<75 years | 2 | 5 | 2 |
| 75-<85 years | 1 | 1 | 2 |
| Sex: Female, Male(Participants) | Group A: Avelumab + Crizotinib | Group B: Avelumab + Lorlatinib | Total |
|---|---|---|---|
| Female | 6 | 19 | 25 |
| Male | 6 | 12 | 18 |
| Race/Ethnicity, Customized(Participants) | Group A: Avelumab + Crizotinib | Group B: Avelumab + Lorlatinib | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 1 | 1 |
| Asian | 8 | 17 | 25 |
| White | 4 | 13 | 17 |
| Race/Ethnicity, Customized(Participants) | Group A: Avelumab + Crizotinib | Group B: Avelumab + Lorlatinib | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 1 | 1 |
| Not Hispanic or Latino | 11 | 30 | 41 |
| Not Reported | 1 | 0 | 1 |
| Age Range(Years) | Group A: Avelumab + Crizotinib | Group B: Avelumab + Lorlatinib | Total |
|---|---|---|---|
| Median | 59.5 (43 to 76) | 54 (30 to 77) | 55 (30 to 77) |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Data sharing details ↗ · www.pfizer.com
Ran from Dec 2015 to primary completion in Feb 2021, 61 months.
Results were first posted in Feb 2022, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jun 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lorlatinib
Carcinoma, Non-Small-Cell Lung →